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SUMMARY
Dabigatran etexilate is emerging as an alternative for vitamin K antagonists, but evidence-
based guidelines for management of intracerebral hemorrhage and acute ischemic stroke
in patients taking this drug are nonexistent. This review summarizes current knowledge
on key pharmacological features and the assessment of dabigatran activity. Pragmatic ap-
proaches are provided for individualized decision taking with regard to hemostatic therapy
and reperfusion strategies in acute stroke patients.
Introduction
Dabigatran is a small molecule that directly inhibits both free and
clot-bound thrombin, independently of endogenous antithrom-
bin. It is the active moiety of the orally bioavailable prodrug, dabi-
gatran etexilate (Pradaxa R©, Boehringer Ingelheim, Ingelheim am
Rhein, Germany) [1]. Based on positive results in pivotal trials, it
has been approved for prophylaxis of venous thromboembolism
in elective hip and knee surgery (150 or 220 mg od) [2–5] and
for the prevention of stroke and systemic embolism in patients
with atrial fibrillation (110 or 150 mg bid) [6]. It has been shown
that dabigatran 150 mg bid is as effective as warfarin for treatment
of acute venous thromboembolism [7], and several clinical trials
in other conditions are ongoing [8]. Given its favorable profile,
it is to be expected that dabigatran will become a part of routine
practice as an alternative for vitamin K antagonists. Despite the
good efficacy/safety balance, clinicians will be confronted with pa-
tients under treatment with dabigatran presenting with intracere-
bral hemorrhage or acute ischemic stroke.
This article describes a practical approach for rapid decision
taking with regard to acute stroke management in patients
taking dabigatran. As clinical evidence and internationally ac-
cepted guidelines with regard to this situation currently are
nonexistent, the options discussed in this article are based on the




Dabigatran’s anticoagulant effect is directly dependent on its
plasma concentration and starts immediately after oral intake,
with peak plasma concentrations and maximal effects within 2–3
h. The bioavailability after oral administration of dabigatran etex-
ilate is 7.2% [1]. After multiple dose administrations in healthy
men, the estimated half-life is 14–17 h and steady-state conditions
are reached within 3 days [9–11]. The drug is predominantly ex-
creted unchanged via the kidneys (∼80%) whereas the remain-
der is excreted via the bile [1]. Patients with poor renal function
may have prolonged excretion rates and elevated plasma con-
centrations of dabigatran [12]. There is no interference with cy-
tochrome P450 drug-metabolizing enzymes. Dabigatran displays
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low (35%) plasma protein binding, implying that displace-
ment interactions are unlikely to affect its pharmacokinetics and
pharmacodynamics [1].
The bleeding risk is increased with concomitant use of P-
glycoprotein inhibitors (quinidine, systemic ketoconazole, vera-
pamil, and amiodarone), antiplatelet drugs and nonsteroidal an-
tiinflammatory drugs (NSAIDs). Ciclosporine, itraconazol, and
tacrolimus are powerful P-glycoprotein inhibitors that based on
in vitro data may carry the same risk as ketoconazole. P-
glycoprotein inducers (rifampicin, carbamazepin, phenytoin, and
St. John’s Wort) may result in decreased plasma levels of dabiga-
tran [13].
Assessment of Dabigatran Activity
In patients with acute stroke, urgent evaluation of dabigatran
plasma concentration is essential for guiding the management
strategy. Currently, neither plasma levels of dabigatran nor its ef-
fect on hemostasis can rapidly and reliably be measured in routine
clinical practice. The assessment of dabigatran activity relies on the
estimation of residual activity based on both pharmacological data
and hemostatic tests.
Estimation of Residual Anticoagulant Activity
Based on Pharmacological Data
When the time since the last drug intake is known, the residual
anticoagulant effect can be estimated based on the half-life and
bioavailability of the drug. The half-life is about 13, 15, 18, and 27
h in volunteers with creatinine clearance >80, 50–80, 30–50, and
<30 mL/min, respectively [12]. Other important determinants of
the bleeding risk include advanced age, comorbidities, and con-
comitant medications (P-glycoprotein inhibitors or inducers, an-
tiplatelet drugs, NSAIDs, and anticoagulants) [13].
Laboratory Analyses of Hemostasis
At clinically relevant plasma concentrations, the prothrombin time
(PT) and its derived international normalized ratio (INR) are only
little and variably affected by dabigatran and therefore are of no
use for evaluating its anticoagulant effect [9].
Prolongation of the activated partial thromboplastin time (aPTT)
occurs with increasing dabigatran plasma concentration, but is less
sensitive at supratherapeutic levels [9, 14]. Thus, aPTT measure-
ment may provide a qualitative indication of dabigatran’s anti-
coagulant activity, but is not suitable for precise quantification
[15, 16].
The thrombin time (TT) displays a linear dose–response curve
for therapeutic concentrations of dabigatran. TT tests are widely
available in hospital laboratories, but cut-off limits cannot be de-
fined because of the wide variation in methodology. The TT is a
sensitive method for determining if any dabigatran is present [14].
Clinical studies on the activated clotting time (ACT) in patients
taking dabigatran have not yet been undertaken. In vitro studies
showed a concentration-dependent increase in ACT which was
linear with dabigatran concentrations up to 250 ng/mL but flat-
tened at higher concentrations (≥500 ng/mL), limiting the utility
of this assay [14].
Clinical experience supports the ecarin clotting time (ECT) as a
sensitive test for measuring anticoagulant activity with superiority
over the aPTT [17], but this assay is not generally available in hos-
pital laboratories and commercial kits have not been validated for
dabigatran [17]. Therefore, ECT cannot yet be recommended for
this indication.
The Hemoclot R© Thrombin Inhibitor assay (Hyphen BioMed,
Neuville-sur-Oise, France) is a sensitized TT that allows quantita-
tive measurement of direct thrombin inhibitor activity in plasma,
thanks to a direct linear relationship between dabigatran concen-
tration and the clotting time [14].
Taken together, the aPTT and TT are the most accessible qual-
itative methods for determining the presence or absence of an-
ticoagulant effect in dabigatran-treated patients. If available, the
Hemoclot R© Thrombin Inhibitor assay can be used for quantitative
assessments.
Acute Intracerebral Hemorrhage
in Patients Taking Dabigatran
In the RE-LY trial, the annual incidence of life-threatening hem-
orrhage was 1.2 and 1.5% for patients treated with 110 and 150
mg dabigatran, respectively, but information on how the bleed-
ings were managed is not available [6]. In contrast to heparins and
vitamin K antagonists, a specific antidote for direct thrombin in-
hibitors is not yet available [18]. The management of patients with
intracerebral hemorrhage while taking dabigatran should be indi-
vidualized based on the extent of dabigatran-related coagulopathy,
stroke severity, and the availability of medical and surgical treat-
ments (Figure 1).
Assessment of Dabigatran-Related Coagulopathy
Patients or their relatives should be questioned with regard to
recent anticoagulant use. Detailed information on dabigatran
dosage, time since last intake, relevant comorbidity (especially re-
nal dysfunction), and concomitant medication (P-glycoprotein in-
hibitors or inducers, antiplatelet drugs, and NSAIDs) should be ob-
tained. A routine blood analysis including complete blood count,
creatinine clearance, and aPTT should urgently be performed. The
Hemoclot R© Thrombin Inhibitor assay can be used for more reli-
able quantitative assessments, if available [14].
Based on the clinical information and the blood analysis, a mul-
tidisciplinary team consisting of an experienced stroke specialist,
a neurosurgeon, and a coagulation expert should decide on the
presence of a clinically relevant dabigatran-related coagulopathy.
General Measures
Basic supportive measures should be applied according to interna-
tionally accepted guidelines [19, 20]. Dabigatran administration
should be discontinued and adequate diuresis should be main-
tained. Preliminary in vitro data indicate that dabigatran etexilate
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Figure 1 A pragmatic approach for management
of patients with intracerebral hemorrhage while
taking dabigatran.
aPTT, activated partial thromboplastin time;
Hemoclot, Hemoclot R© Thrombin Inhibitor assay.
can be successfully adsorbed by standard activated charcoal ther-
apy [14]. It may be advised to orally administer charcoal (1g/kg
body weight) if the time to last intake of dabigatran does not ex-
ceed 2 h. Because of lack of clinical data on removal of dabiga-
tran from plasma via hemoperfusion over a charcoal filter, this
technique cannot be recommended currently. In case of clini-
cally relevant anemia, transfusion of packed red cells may be in-
dicated. Thrombocyte transfusion may be considered for patients
with thrombocyte count <60,000 per μL or the combined use of
dabigatran and an antiplatelet drugs [16, 21]. In accordance with
international guidelines, surgical intervention may be an option,
preferably after normalization of the coagulation [19, 20].
Hemostatic Agents for Reversal of
Dabigatran-Related Coagulopathy
The use of hemostatic therapies in dabigatran-related bleeding is
merely based on preclinical data and case reports [22]. Hemostatic
agents are not registered for this indication and have thrombo-
genic potential [23]. They should only be used in patients with
life-threatening hemorrhages after thorough risk–benefit evalua-
tion [14].
Recombinant activated factor VII at a dose of 80 μg/kg (Novo-
Seven R©, Novo Nordisk, Bagsvaerd, Denmark) reduces hematoma
growth in patients with acute intracerebral hemorrhage, however,
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without improvement of clinical outcome and at a small increased
risk of thromboembolic events [24, 25]. Preclinical data suggest
that recombinant activated factor VII may antagonize the antico-
agulant effect of dabigatran [26].
There are several types of prothrombin complex concen-
trates, but data with regard to dabigatran are only available for
Cofact R© (Sanquin, Amsterdam, The Netherlands), Confidex R©
(CSL Behring, Marburg, Germany), and Feiba VH R© (Baxter, Vi-
enna, Austria). Administration of a single bolus of Cofact R© 50
IU/kg in six healthy volunteers taking dabigatran 150 mg bid did
not reverse its anticoagulant effect, as measured by aPTT, ECT,
and TT [27]. Confidex R© showed reduced bleeding with high dose
dabigatran in a rabbit model [18]. Feiba VH R© reduced bleeding
due to high dose dabigatran in a rat model and in vitro studies us-
ing human plasma showed complete reversal of the dabigatran-
inhibited endogenous thrombin potential [14]. There is neither
expected benefit nor experience with the use of protamine sul-
fate, vitamin K, desmopressin, aprotinin, tranexamic acid, and
aminocaproic acid in patients receiving dabigatran. There is no
presumptive evidence that fresh frozen plasma can reverse the
anticoagulant effect of dabigatran and the risk of complications
(transfusion-related acute lung injury, circulatory overload, and
transmission of infectious diseases) further argue against its use
[28].
Hemodialysis
Dabigatran is characterized by low protein binding and is dialyz-
able. Results from an open-label study in patients with end-stage
renal failure on maintenance hemodialysis show a decline of sys-
temic dabigatran concentrations by 60–69% in a 4 h dialysis ses-
sion [12]. The clinical utility of this approach is unknown, but it
can be an option in life-threatening situations, especially in pa-
tients with renal dysfunction.
Restart of Dabigatran
Based on the results of a decision analysis, it is advised that
survivors of intracerebral hemorrhage with atrial fibrillation
should not be offered long-term anticoagulation with vitamin K-
antagonists, except those at a particularly high risk for throm-
boembolic stroke or low risk of hemorrhage recurrence [29]. In
the absence of clinical data, it seems acceptable to advise against
restart of dabigatran after intracerebral hemorrhage.
Management of Acute Infarction
in Patients Taking Dabigatran
Despite treatment with dabigatran, the annual risk of ischemic
stroke remains about 1% in patients with atrial fibrillation [6].
Care of patients presenting with acute ischemic stroke while tak-
ing dabigatran should be based on an individualized risk–benefit
analysis, taking the bleeding risk and the stroke severity into ac-
count (Figure 2).
Assessment of Dabigatran-Related Coagulopathy
The presence of a clinically relevant coagulopathy should be evalu-
ated by a multidisciplinary team, based on available pharmacologi-
cal information (dosage, time since last intake, renal function, and
concomitant medication) and coagulation tests (aPTT, Hemoclot R©
Thrombin Inhibitor assay).
General Measures
Concordant with international guidelines, patients should be
hospitalized in stroke units providing care through standard-
ized orders. Special attention should be given to rapid detection
and correction of hypoxia, hypoglycemia, fever, cardiac arrhyth-
mias, severe arterial hypotension or hypertension. Decompres-
sive craniectomy for space occupying hemispheric or cerebellar
ischemic strokes may be considered after normalization of the
coagulation [30, 31].
Reversal of Dabigatran’s Anticoagulant Effect
In case of an acute thromboembolic event, it could be an option to
first administer hemostatic agents for reversal of the coagulopathy
before initiating thrombolytic therapy. However, the prothrom-
botic risks of these agents are likely to outweigh the potential
benefits in patients (taking dabigatran) with acute ischemic stroke
[32], and their use may therefore not be advised for this indica-
tion until more clinical data become available. Relevant declines
in dabigatran concentration have been obtained by hemodialysis
[12], but this technique is time consuming and will prevent initia-
tion of thrombolytic therapy within the appropriate time window
in most patients.
Reperfusion Strategies
The clinical experience with reperfusion therapy in patients tak-
ing dabigatran is limited to intravenous administration of recom-
binant tissue plasminogen activator (IV rtPA) in three cases– two
with good outcome [33, 34] and one patient suffering from fatal
intracerebral hemorrhage [35]. IV rtPA is the only specific treat-
ment that has been approved for acute ischemic stroke with class
I recommendation and evidence level A [36]. As patients receiv-
ing therapeutic doses of anticoagulants before stroke onset were
excluded from fibrinolytic therapy in all randomized clinical trials,
little is known about the bleeding risk and efficacy of this combina-
tion [37]. Conflicting results can be found with regard to the safety
of IV rtPA in patients taking vitamin K antagonists [38, 39], but it
is generally accepted that this therapy is contraindicated in those
with INR ≥ 1.7 because of a supposedly higher risk of hemorrhage
[36]. In vitro studies indicate that dabigatran enhances the effect
of thrombolytics [40], and the combined treatment of the direct
thrombin inhibitor argatroban and rtPA resulted in higher recanal-
ization rates at the expense of a moderately increased bleeding risk
[41].
According to international guidelines, patients without rel-
evant coagulopathy should receive IV rtPA if the criteria are
met [30–32], but in case of dabigatran-related coagulopathy,
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Figure 2 A pragmatic approach formanagement of patients with acute ischemic strokewhile taking dabigatran. aPTT, activated partial thromboplastin time;
Hemoclot, Hemoclot R© Thrombin Inhibitor assay; IA; intraarterial; IV rtPA, intravenous recombinant tissue plasminogen activator.
stroke severity and the expected outcome of spontaneous evo-
lution should be weighed against the risks and benefits of
reperfusion therapies. Comorbidity (e.g., renal dysfunction) or
concomitant medication associated with increased bleeding
diathesis (P-glycoprotein inhibitors, antiplatelet drugs, NSAIDs,
and anticoagulants) are reasons to refrain from thrombolysis. In
patients with rapidly improving stroke or mild deficits, the sus-
pected risk of fibrinolytic therapy may exceed the clinical benefit
[42]. The bleeding risk may even be higher in severe stroke, but
so is the probability of unfavorable spontaneous evolution [43].
Multimodal computed tomography or magnetic resonance imag-
ing can be useful for confirmation of acute cerebral ischemia, iden-
tification of predictors of intracranial hemorrhage, and selection of
patients suffering from large artery occlusion [44].
Endovascular treatment by intra-arterial thrombolysis,
thrombectomy, thromboaspiration, or thrombus disruption
can be used in patients who are ineligible for IV rtPA [30, 31,
45]. Mechanical recanalization could be the treatment of choice
in patients with coagulopathy because these techniques do not
interfere with the coagulation cascade. It may also be reasonable
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to consider intraarterial thrombolysis, because this is associated
with a lower risk of symptomatic intracerebral hemorrhage than
IV rtPA [46].
Although there is no proof that reperfusion procedures are safe
in patients taking dabigatran, IV rtPA may be an option in dis-
abling or life-threatening stroke if endovascular approaches are
unavailable [33, 34]. Adjunctive use of anticoagulants or an-
tiplatelet drugs should be avoided and patients should be moni-
tored closely [16]. Retrospective study of the three cases treated
with IV rtPA while taking dabigatran underlines the need for
a multidisciplinary assessment [33–35]. Although good outcome
was obtained in two patients with a favorable risk/benefit pro-
file, the patient with the fatal intracerebral hemorrhage indeed
exhibited a high bleeding risk: initiation of IV rtPA at 6 h after last
dose of dabigatran (therapeutic plasma concentrations must have
been present) and pretreatment with enoxaparin. On the other
hand, secondary intracerebral hemorrhage might have occurred
in this patient even without rtPA or dabigatran, because of hyper-
glycemia and extensive cerebral infarction [35, 47].
Restart of Dabigatran
In patients suffering from ischemic stroke despite treatment with
dabigatran, the risk of recurrent cardio-embolism has to be bal-
anced against the risk of hemorrhagic transformation of the in-
farction. Until data on the latter become available for dabigatran,
it may be advisable to withhold anticoagulants for 10–14 days in
major stroke and low risk of stroke recurrence, as is common prac-
tice for patients treated with vitamin K antagonists [16, 48]. Data
with regard to the choice of anticoagulants (vitamin K antagonists,
direct thrombin inhibitors, or factor Xa inhibitors) in patients suf-
fering from ischemic stroke despite taking dabigatran are not avail-
able. Differences in therapeutic efficacy and safety between direct
thrombin inhibitors and factor Xa inhibitors are matter of on-going
debate. For this reason, we would not routinely change the anti-
coagulant regime but rather restart dabigatran.
Conclusion
Alternatives for vitamin K antagonists are emerging under the
form of direct thrombin inhibitors (dabigatran etexilate) and di-
rect factor Xa inhibitors [49–51]. It is to be expected that clini-
cians will increasingly be faced with intracerebral hemorrhage and
acute ischemic stroke in patients taking these new anticoagulants.
Pragmatic approaches for tackling these situations are needed un-
til evidence-based guidelines become available. Individualized de-
cisions should rapidly be obtained by multidisciplinary teams eval-
uating the extent of the coagulopathy and the risks and benefits of
various therapeutic options.
Several actions can be taken to improve acute stroke care in pa-
tients taking dabigatran. First of all, we should engage in a registry
of clinical data, therapeutic interventions, and outcome of patients
suffering from stroke under treatment with dabigatran. Second,
assays for rapid qualitative evaluation of dabigatran plasma lev-
els should be available in any routine laboratory, and standard-
ized quantitative measurements should be provided by laborato-
ries with experience in hemostasis. Third, research on antagonists
for dabigatran is to be encouraged. Fourth, safety data are needed
with regard to thrombolysis for acute ischemic stroke.
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